RESUMEN
BACKGROUND: The Duffy antigen receptor for chemokines (DARC) is an atypical receptor that regulates pro-inflammatory cytokines. However, the role of DARC in asthma pathophysiology is unknown. OBJECTIVE: To determine the role of DARC in allergic airways disease in mice, and the association between DARC single nucleotide polymorphisms (SNPs) and clinical outcomes in patients with asthma. METHODS: Mice with targeted disruption of the Darc gene (Darc∆E2 ) or WT mice were challenged over 3 weeks with house dust mite (HDM) antigen. Allergic airways disease was assessed 24 hours and 7 days following the final challenge. Additionally, associations between DARC SNPs and clinical outcomes were analysed in a cohort of poorly controlled asthmatics. RESULTS: Total airway inflammation following HDM did not differ between Darc∆E2 and WT mice. At 24 hours, Darc∆E2 mice had increased airway hyperresponsiveness; however, at 7 days airway hyperresponsiveness had completely resolved in Darc∆E2 but persisted in WT mice. In poorly controlled asthmatics, DARC SNPs were associated with worse asthma control at randomization and subsequent increased risk of healthcare utilization (odds ratio 3.13(1.37-7.27), P=.0062). CONCLUSIONS AND CLINICAL RELEVANCE: Our animal model and human patient data suggest a novel role for DARC in the temporal regulation in asthma pathophysiology and symptoms.
Asunto(s)
Asma , Quimiocinas , Sistema del Grupo Sanguíneo Duffy , Receptores de Superficie Celular , Animales , Femenino , Humanos , Masculino , Ratones , Antígenos Dermatofagoides/inmunología , Asma/diagnóstico , Asma/etiología , Asma/metabolismo , Quimiocinas/metabolismo , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Sistema del Grupo Sanguíneo Duffy/genética , Sistema del Grupo Sanguíneo Duffy/metabolismo , Expresión Génica , Sitios Genéticos , Leucocitos/inmunología , Leucocitos/metabolismo , Leucocitos/patología , Ratones Noqueados , Neutrófilos/inmunología , Neutrófilos/metabolismo , Neutrófilos/patología , Aceptación de la Atención de Salud , Evaluación del Resultado de la Atención al Paciente , Fenotipo , Polimorfismo de Nucleótido Simple , Pronóstico , Receptores de Superficie Celular/genética , Receptores de Superficie Celular/metabolismo , Hipersensibilidad Respiratoria/diagnóstico , Hipersensibilidad Respiratoria/etiología , Hipersensibilidad Respiratoria/metabolismo , Mucosa Respiratoria/inmunología , Mucosa Respiratoria/metabolismo , Índice de Severidad de la EnfermedadRESUMEN
Heterogeneous therapeutic responses to leukotriene modifiers (LTMs) are likely due to variation in patient genetics. Although prior candidate gene studies implicated multiple pharmacogenetic loci, to date, no genome-wide association study (GWAS) of LTM response was reported. In this study, DNA and phenotypic information from two placebo-controlled trials (total N=526) of zileuton response were interrogated. Using a gene-environment (G × E) GWAS model, we evaluated 12-week change in forced expiratory volume in 1 second (ΔFEV1) following LTM treatment. The top 50 single-nucleotide polymorphism associations were replicated in an independent zileuton treatment cohort, and two additional cohorts of montelukast response. In a combined analysis (discovery+replication), rs12436663 in MRPP3 achieved genome-wide significance (P=6.28 × 10(-08)); homozygous rs12436663 carriers showed a significant reduction in mean ΔFEV1 following zileuton treatment. In addition, rs517020 in GLT1D1 was associated with worsening responses to both montelukast and zileuton (combined P=1.25 × 10(-07)). These findings implicate previously unreported loci in determining therapeutic responsiveness to LTMs.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Sitios Genéticos , Leucotrienos/metabolismo , Acetatos/uso terapéutico , Asma/genética , Asma/metabolismo , Estudios de Cohortes , Ciclopropanos , Interacción Gen-Ambiente , Estudio de Asociación del Genoma Completo , Genotipo , Humanos , Hidroxiurea/análogos & derivados , Hidroxiurea/uso terapéutico , Fenotipo , Polimorfismo de Nucleótido Simple , Quinolinas/uso terapéutico , SulfurosRESUMEN
Airway hyper-responsiveness (AHR) has long been considered a cardinal feature of asthma. The development of the measurement of AHR 40 years ago initiated many important contributions to our understanding of asthma and other airway diseases. However, our understanding of AHR in asthma remains complicated by the multitude of potential underlying mechanisms which in reality are likely to have different contributions amongst individual patients. Therefore, the present review will discuss the current state of understanding of the major mechanisms proposed to contribute to AHR and highlight the way in which AHR testing is beginning to highlight distinct abnormalities associated with clinically relevant patient populations. In doing so we aim to provide a foundation by which future research can begin to ascribe certain mechanisms to specific patterns of bronchoconstriction and subsequently match phenotypes of bronchoconstriction with clinical phenotypes. We believe that this approach is not only within our grasp but will lead to improved mechanistic understanding of asthma phenotypes and we hoped to better inform the development of phenotype-targeted therapy.
Asunto(s)
Asma/diagnóstico , Asma/etiología , Hipersensibilidad Respiratoria/diagnóstico , Hipersensibilidad Respiratoria/etiología , Humanos , Fenotipo , Pruebas de Función RespiratoriaRESUMEN
Reversibility of airway obstruction in response to ß2-agonists is highly variable among asthmatics, which is partially attributed to genetic factors. In a genome-wide association study of acute bronchodilator response (BDR) to inhaled albuterol, 534 290 single-nucleotide polymorphisms (SNPs) were tested in 403 white trios from the Childhood Asthma Management Program using five statistical models to determine the most robust genetic associations. The primary replication phase included 1397 polymorphisms in three asthma trials (pooled n=764). The second replication phase tested 13 SNPs in three additional asthma populations (n=241, n=215 and n=592). An intergenic SNP on chromosome 10, rs11252394, proximal to several excellent biological candidates, significantly replicated (P=1.98 × 10(-7)) in the primary replication trials. An intronic SNP (rs6988229) in the collagen (COL22A1) locus also provided strong replication signals (P=8.51 × 10(-6)). This study applied a robust approach for testing the genetic basis of BDR and identified novel loci associated with this drug response in asthmatics.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Polimorfismo de Nucleótido Simple , Sitios de Carácter Cuantitativo , Adolescente , Agonistas de Receptores Adrenérgicos beta 2/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Asma/genética , Broncodilatadores/administración & dosificación , Niño , Preescolar , Ensayos Clínicos como Asunto , Femenino , Estudio de Asociación del Genoma Completo , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto JovenRESUMEN
A pro-asthmatic culture milieu and ß2-agonist (isoproterenol) were previously shown to regulate the expression of select transcription factors (TFs) within human airway epithelial and smooth muscle cells. This study tests 1116 single-nucleotide polymorphisms (SNPs) across 98 of these TF genes for association with bronchodilator response (BDR) in asthma patients. Genotyping was conducted using the Illumina HumanHap550v3 Beadchip in 403 non-Hispanic White asthmatic children and their parents. SNPs were evaluated for association with BDR using family and population-based analyses. Forty-two SNPs providing P-values <0.1 in both analyses were then genotyped in three adult asthma trials. One SNP 5' of the thyroid hormone receptor-ß gene was associated with BDR in the childhood population and two adult populations (P-value=0.0012). This investigation identified a novel locus for inter-individual variability in BDR and represents a translation of a cellular drug-response study to potential personalization of clinical asthma management.
Asunto(s)
Asma/genética , Células Epiteliales/metabolismo , Miocitos del Músculo Liso/metabolismo , Receptores beta de Hormona Tiroidea/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Asma/tratamiento farmacológico , Asma/patología , Biomarcadores Farmacológicos/metabolismo , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Niño , Preescolar , Células Epiteliales/patología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Estudios de Asociación Genética , Haplotipos , Humanos , Masculino , Persona de Mediana Edad , Miocitos del Músculo Liso/patología , Polimorfismo de Nucleótido Simple , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
BACKGROUND: Asthma is a common chronic respiratory disease in children and adults. An important genetic component to asthma susceptibility has long been recognized, most recently through the identification of several genes (e.g., ORMDL3, PDE4D, HLA-DQ, and TLE4) via genome-wide association studies. OBJECTIVE: To identify genetic variants associated with asthma affection status using genome-wide association data. METHODS: We describe results from a genome-wide association study on asthma performed in 3855 subjects using a panel of 455 089 single nucleotide polymorphisms (SNPs). RESULT: The genome-wide association study resulted in the prioritization of 33 variants for immediate follow-up in a multi-staged replication effort. Of these, a common polymorphism (rs9272346) localizing to within 1 Kb of HLA-DQA1 (chromosome 6p21.3) was associated with asthma in adults (P-value = 2.2E-08) with consistent evidence in the more heterogeneous group of adults and children (P-value = 1.0E-04). Moreover, some genes identified in prior asthma GWAS were nominally associated with asthma in our populations. CONCLUSION: Overall, our findings further replicate the HLA-DQ region in the pathogenesis of asthma. HLA-DQA1 is the fourth member of the HLA family found to be associated with asthma, in addition to the previously identified HLA-DRA, HLA-DQB1 and HLA-DQA2.
Asunto(s)
Asma/genética , Predisposición Genética a la Enfermedad , Antígenos HLA-DQ/genética , Cadenas alfa de HLA-DQ/genética , Polimorfismo de Nucleótido Simple , Adolescente , Adulto , Anciano , Asma/epidemiología , Asma/fisiopatología , Niño , Preescolar , Ensayos Clínicos como Asunto , Femenino , Estudio de Asociación del Genoma Completo , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
Mast cells are the main effector cells of immediate hypersensitivity and anaphylaxis. Their role in the development of allergen-induced airway hyperresponsiveness (AHR) is controversial and based on indirect evidence. To address these issues, mast cell-deficient mice (W/W v) and their congenic littermates were sensitized to ovalbumin (OVA) by intraperitoneal injection and subsequently challenged with OVA via the airways. Comparison of OVA-specific immunoglobulin E (IgE) levels in the serum and numbers of eosinophils in bronchoalveolar lavage fluid or lung digests showed no differences between the two groups of mice. Further, measurements of airway resistance and dynamic compliance at baseline and after inhalation of methacholine were similar. These data indicate that mast cells or IgE-mast cell activation is not required for the development of eosinophilic inflammation and AHR in mice sensitized to allergen via the intraperitoneal route and challenged via the airways.
Asunto(s)
Hiperreactividad Bronquial/patología , Eosinófilos/patología , Mastocitos/patología , Resistencia de las Vías Respiratorias/inmunología , Animales , Hiperreactividad Bronquial/fisiopatología , Líquido del Lavado Bronquioalveolar/inmunología , Femenino , Inmunoglobulina E/biosíntesis , Inmunoglobulina G/biosíntesis , Pulmón/inmunología , Pulmón/patología , Rendimiento Pulmonar/inmunología , Mastocitos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunologíaRESUMEN
The composite vagus nerve was stimulated during intravenous infusion of 5-hydroxytryptamine in cats subjected to pharmacologic autonomic blockade with atropine, propranolol, and phentolamine. Bronchial caliber, as assessed by changes in pulmonary resistance, demonstrated a marked dilatation, and dilatation could still be demonstrated after preliminary treatment with reserpine. By stimulating the component branches of the vagus nerve, it was determined that the parasympathetic branch is responsible for this phenomenon.
Asunto(s)
Bronquios/inervación , Parasimpatolíticos/farmacología , Simpaticolíticos/farmacología , Nervio Vago/fisiología , Resistencia de las Vías Respiratorias/efectos de los fármacos , Animales , Gatos , Estimulación EléctricaRESUMEN
We have previously reported that human eosinophil granule major basic protein and synthetic cationic proteins such as poly-L-arginine and poly-L-lysine, can increase airway responsiveness in vivo. In the present study, we have investigated whether activation of sensory C-fibers is important in this phenomenon. Dose-response curves to methacholine were constructed before and 1 h after intratracheal instillation of poly-L-lysine in anaesthetized spontaneously breathing rats, and the concentration of methacholine required to induce a doubling in total lung resistance was calculated. Poly-L-lysine induced a fivefold increase in airway responsiveness, which was inhibited by neonatal capsaicin treatment and potentiated by phosphoramidon (100 micrograms/ml). Furthermore, pretreatment with either CP, 96-345, or RP-67580 two selective NK-1 receptor antagonists inhibited poly-L-lysine-induced airway hyperresponsiveness and plasma protein extravasation. In vitro, cationic proteins stimulated the release of calcitonin gene-related peptide-like immunoreactivity from perfused slices of the main bronchi. Our results demonstrate that cationic proteins can activate sensory C-fibers in the airways, an effect which is important in the subsequent development of airway hyperresponsiveness and plasma protein extravasation. Cationic proteins may therefore function as a link between inflammatory cell accumulation and sensory nerve activation.
Asunto(s)
Bronquios/fisiología , Neuronas Aferentes/fisiología , Péptidos/farmacología , Transducción de Señal/fisiología , Sustancia P/fisiología , Animales , Proteínas Sanguíneas/metabolismo , Bronquios/efectos de los fármacos , Bronquios/inervación , Péptido Relacionado con Gen de Calcitonina/análisis , Permeabilidad Capilar/fisiología , Capsaicina/farmacología , Cationes/farmacología , Femenino , Glicopéptidos/farmacología , Masculino , Cloruro de Metacolina/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Neuronas Aferentes/efectos de los fármacos , Polilisina/farmacología , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacosRESUMEN
In the current series of experiments we investigated the role of bradykinin in airway hyperresponsiveness induced by human eosinophil-granule major basic protein (MBP). Bronchoalveolar lavage was performed after intratracheal instillation of MBP or poly-L-lysine in anesthetized, intubated rats, and levels of immunoreactive kinins and kallikrein-like activity were determined. Both MBP and poly-L-lysine induced a three- and eightfold increase in levels of kallikrein-like activity and i-kinins, respectively. To determine whether kinin production is required for the development of airway hyperresponsiveness induced by cationic proteins, dose-response curves to methacholine were constructed before and 1 h after intratracheal instillation of either MBP or poly-L-lysine (100 micrograms). MBP and poly-L-lysine induced an increase in airway responsiveness, which was inhibited by pretreatment with a selective BK-2 receptor antagonist, NPC 17713 (250 micrograms/ml). Our results demonstrate that MBP and poly-L-lysine activate kallikrein and stimulate the generation of i-kinins in vivo, an effect that may be related to the cationic charge of these proteins. Furthermore, the ability of these proteins to increase airway responsiveness appears to be dependent on the generation of i-kinins.
Asunto(s)
Proteínas Sanguíneas/farmacología , Bradiquinina/fisiología , Hipersensibilidad/inmunología , Mediadores de Inflamación/farmacología , Sistema Respiratorio/inmunología , Ribonucleasas , Secuencia de Aminoácidos , Animales , Bradiquinina/biosíntesis , Broncoconstricción/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Activación Enzimática , Proteínas en los Gránulos del Eosinófilo , Eosinófilos/inmunología , Femenino , Humanos , Calicreínas/biosíntesis , Masculino , Cloruro de Metacolina/farmacología , Datos de Secuencia Molecular , Oligopéptidos/farmacología , Poliaminas/farmacología , Polielectrolitos , Polilisina/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
Early-phase reactions (EPRs) and late-phase reactions (LPRs) are characteristic features of bronchial asthma, although the pathogenetic mechanisms responsible for each of the responses are not fully defined. A murine model of EPRs and LPRs was developed to investigate the role of IL-5 and eosinophils in development of both responses. After initial intraperitoneal sensitization and airway challenge to ovalbumin (OVA), mice were provoked by additional exposure to OVA. An EPR, characterized by a transient increase in airway responsiveness, was observed 5-30 minutes after antigen provocation. This response was followed by an LPR that reached its maximum at 6 hours after challenge and was characterized by increased airway responsiveness and significant lung eosinophilia. The EPR was blocked by cromoglycate and albuterol, whereas the LPR was abolished by cromoglycate and hydrocortisone. Before provocation with allergen, administration of anti-IL-5 antibody prevented the influx of eosinophils into the lung tissue and abolished the LPR but not EPR. These results suggest that IL-5 and eosinophils are essential for development of the LPR, but not EPR, in this model.
Asunto(s)
Asma/inmunología , Movimiento Celular/inmunología , Eosinófilos/fisiología , Interleucina-5/fisiología , Administración por Inhalación , Alérgenos/administración & dosificación , Alérgenos/inmunología , Animales , Antiasmáticos/farmacología , Anticuerpos Monoclonales/administración & dosificación , Asma/patología , Asma/fisiopatología , Asma/prevención & control , Hiperreactividad Bronquial/inmunología , Líquido del Lavado Bronquioalveolar/inmunología , Eosinófilos/inmunología , Eosinófilos/patología , Inmunización , Interleucina-5/inmunología , Interleucina-5/metabolismo , Recuento de Leucocitos , Pulmón/inmunología , Pulmón/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunología , Factores de TiempoAsunto(s)
Asma/inmunología , Sistema Respiratorio/inmunología , Linfocitos T/inmunología , Animales , Asma/etiología , Asma/genética , Trasplante de Médula Ósea , Cloruro de Metacolina/farmacología , Ratones , Ratones Endogámicos C57BL , Sistema Respiratorio/efectos de los fármacos , Especificidad de la EspecieAsunto(s)
Asma , Eosinofilia/inmunología , Eosinófilos/inmunología , Inflamación , Pulmón/inmunología , Nariz/inmunología , Asma/diagnóstico , Asma/inmunología , Asma/fisiopatología , Eosinofilia/diagnóstico , Eosinófilos/citología , Humanos , Inflamación/inmunología , Inflamación/fisiopatología , Recuento de Leucocitos , Líquido del Lavado Nasal , Esputo/inmunologíaRESUMEN
Intravenous infusions of perfluorochemical emulsions, combined with administration of inspired oxygen or carbogen have been found to improve tumor oxygenation and increase the response of solid tumors in animals to radiotherapy. Fluosol-DA 20 per cent, the only perfluorochemical emulsion currently approved for testing in humans in the United States, has recently entered clinical trials as an adjunct to radiotherapy in the treatment of head and neck carcinoma. The studies reported here were undertaken as part of our laboratory evaluation of the safety and clinical potential of this oxygen-transport fluid as an adjunct to cancer therapy; they asked whether single or multiple treatments with Fluosol and an oxygen-enriched atmosphere produced immunologic perturbations, pulmonary damage, or other effects which altered the development of artificial lung metastases in experimental animals. Neither single nor multiple treatments with clinically relevant regimens of Fluosol and carbogen (95 per cent O2/5 per cent CO2) had any effect on the development of lung nodules from intravenously injected EMT6 tumor cells.
Asunto(s)
Fluorocarburos/farmacología , Metástasis de la Neoplasia , Animales , Peso Corporal/efectos de los fármacos , Dióxido de Carbono/farmacología , Combinación de Medicamentos/farmacología , Femenino , Derivados de Hidroxietil Almidón , Neoplasias Pulmonares/secundario , Neoplasias Mamarias Experimentales/patología , Ratones , Tamaño de los Órganos/efectos de los fármacos , Oxígeno/farmacologíaRESUMEN
Tumor growth and tumor cell survival endpoints were used to examine the effects of a perfluorochemical emulsion, Fluosol-DA, 20%, and carbogen (95% O2/5% CO2) on EMT6 mouse mammary tumors in BALB/c mice. These studies defined the effects of the Fluosol dose on the hematocrit and fluorocrit of the mice and on the radiation response of the tumors. The effect of varying the duration of carbogen breathing before irradiation was examined; times of 5-60 min gave similar enhancements of tumor radiosensitivity. Potentiating effects were not observed when the tumors were irradiated 1-3 days after Fluosol injection, probably reflecting the observed clearance of the perfluorochemicals from the circulating blood. Fluosol injected 30 min-2 days before irradiation did not alter the radiation response of tumors in air-breathing or N2-asphyxiated mice. Together, these studies provided additional support for the hypothesis that the potentiation of tumor radiation response observed after treatment with Fluosol plus carbogen results from changes in O2 delivery to the hypoxic tumor cells by oxygenated perfluorochemical particles. This confirms the conclusion drawn on the basis of the observed changes in the tumor cell survival curve. Studies of tumor cell survival, tumor cell yield, tumor growth, and artificial lung metastasis formation revealed no effects of Fluosol treatment (without irradiation) on tumor progression or metastasis. Studies examining the effects of Fluosol plus carbogen on the growth of tumors irradiated with 5 Gy showed that the changes in tumor radiosensitivity observed using cell survival endpoints also occurred in tumors left in situ after irradiation with a radiation dose similar to those used in some clinical trials.
Asunto(s)
Dióxido de Carbono/uso terapéutico , Fluorocarburos/uso terapéutico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Oxígeno/uso terapéutico , Animales , Terapia Combinada , Combinación de Medicamentos/uso terapéutico , Derivados de Hidroxietil Almidón , Neoplasias Mamarias Experimentales/radioterapia , Ratones , Ratones Endogámicos BALB CRESUMEN
The effect of treatment with the hypoxic cell radiosensitizer misonidazole on the formation of artificial lung metastases was examined. Both single treatments with large doses of misonidazole and fractionated treatments with smaller doses of misonidazole were found to increase the number of lung tumors developing after intravenous injection of EMT6 mouse mammary carcinoma cells. The immunologic and physiologic effects of the nitroimidazole were postulated to be responsible for the enhancement of lung tumor formation.
Asunto(s)
Neoplasias Pulmonares/secundario , Neoplasias Mamarias Experimentales/patología , Misonidazol/toxicidad , Nitroimidazoles/toxicidad , Fármacos Sensibilizantes a Radiaciones/toxicidad , Animales , Línea Celular , Femenino , Neoplasias Pulmonares/patología , Ratones , Ratones Endogámicos BALB C , Trasplante de NeoplasiasRESUMEN
The effect on cell-mediated immunity of two hypoxic cell radiosensitizers, metronidazole and misonidazole, was examined. Immunocompetence was assayed by measuring delayed hypersensitivity reactions in mice sensitized on the abdomen with 2,4-dinitro-1-fluorobenzene (DNFB) and subsequently challenged on the ears with DNFB. Single and fractionated treatments with misonidazole or metronidazole were found to suppress delayed hypersensitivity reactions to DNFB. This finding is in agreement with other data in the literature which show that many imidazoles, including nitroimidazoles, inhibit aspects of the cell-mediated immune response in animals and man. The potential immunosuppressive effects of nitroheterocyclic radiosensitizers should be considered when these agents are evaluated in the laboratory or used in the clinic.
Asunto(s)
Hipersensibilidad Tardía/inmunología , Metronidazol/inmunología , Misonidazol/inmunología , Nitroimidazoles/inmunología , Fármacos Sensibilizantes a Radiaciones/inmunología , Animales , Dinitrofluorobenceno , Hipersensibilidad a las Drogas/inmunología , Femenino , Hipersensibilidad Tardía/inducido químicamente , Masculino , Ratones , Ratones Endogámicos BALB C , Organismos Libres de Patógenos EspecíficosRESUMEN
The effect of pre-treatment with the perfluorochemical emulsion, Fluosol-DA, on the radiation response of normal tissues and EMT6 mammary tumors in BALB/c mice was examined. Pre-treating tumor-bearing mice with .015 ml/g of Fluosol and 30 min of carbogen (95% O2/5% CO2) increased the number of tumor cells killed by irradiation with doses of 2.5-20 Gy; the change in the radiation dose-response curve was consistent with a reduction in the hypoxic fraction. Fluosol did not alter the response of tumors in air-breathing or N2-asphyxiated mice and carbogen alone did not alter the radiation response of this tumor significantly. Carbogen treatments 5-60 min in duration produced similar enhancements of tumor radiosensitivity in Fluosol-treated animals. Pre-treatment with Fluosol plus carbogen also increased the number of tumor cells killed by a fractionated regimen of four 2.5 Gy fractions given over 2 days. Pre-treatment with Fluosol-DA plus carbogen, therefore, increased the antineoplastic effects of radiotherapy in both single-dose and multi-fraction radiation regimens. In contrast, Fluosol did not increase the effect of radiation on the partially committed (CFU-GM) or pluripotent (CFU-S) stem cells of the bone marrow or on the CFU-GM of the spleen. The radiation response of the skin was only slightly enhanced by pre-treatment with Fluosol plus carbogen. These data show that treatment of mice with perfluorochemical emulsions plus carbogen can produce therapeutic gain by improving the radiation response of solid tumors, without producing an equivalent increase in the radiation response of potentially dose-limiting normal tissues. These findings encourage further evaluations of these agents as adjuncts to clinical radiotherapy.
Asunto(s)
Fluorocarburos/uso terapéutico , Neoplasias Experimentales/radioterapia , Fármacos Sensibilizantes a Radiaciones/uso terapéutico , Animales , Dióxido de Carbono/uso terapéutico , Terapia Combinada , Combinación de Medicamentos/uso terapéutico , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/efectos de la radiación , Derivados de Hidroxietil Almidón , Ratones , Neoplasias Experimentales/tratamiento farmacológico , Oxígeno/fisiología , Oxígeno/uso terapéutico , Piel/efectos de los fármacos , Piel/efectos de la radiaciónRESUMEN
Perfluorochemical emulsions are being examined in many laboratory and clinical studies as possible adjuncts to radiotherapy and chemotherapy. The studies reported here examine the clinical potential of hyperbaric oxygen (HBO) in combination with a highly concentrated perfluorochemical emulsion (Oxygent) containing 100% w/v perfluorooctylbromide (PFOB). HBO alone produced only a small improvement in the radiation response of BA1112 tumors in WAG/rij rats, while regimens combining HBO with Oxygent produced much greater radiation sensitization. A sham emulsion, formulated without the O2-carrying PFOB, did not alter the radiation response of the tumors in comparison with that seen with HBO alone. Neither HBO nor Oxygent plus HBO altered the radiosensitivity of bone marrow progenitor cells in BALB/c mice. HBO alone augmented skin reactions in BALB/c mice, but addition of Oxygent did not alter the skin reactions in comparison to those seen with HBO alone. Regimens combining Oxygent with HBO selectively increased the radiation sensitivity of tumors relative to normal tissues, thereby enhancing the therapeutic ratio. These results support the potential usefulness of perfluorochemical emulsions and HBO in clinical radiation therapy.
Asunto(s)
Fluorocarburos/farmacología , Oxigenoterapia Hiperbárica , Fármacos Sensibilizantes a Radiaciones/farmacología , Rabdomiosarcoma/radioterapia , Animales , Ensayo de Unidades Formadoras de Colonias , Emulsiones , Femenino , Granulocitos , Hidrocarburos Bromados , Masculino , Ratones , Ratones Endogámicos BALB C , Células Tumorales Cultivadas/efectos de la radiaciónRESUMEN
The effect of a concentrated perfluorooctylbromide emulsion (Oxygent) on the radiosensitivity and oxygenation of solid tumors was examined using EMT6 mammary tumors in BALB/c mice and BA1112 rhabdomyosarcomas in WAG/rij rats. Treatment with Oxygent plus carbogen or oxygen breathing increased the radiosensitivity of both tumors. Analysis of tumor cell survival data and polarographic measurements of intratumoral pO2 indicated that this potentiation reflected an increase in the proportion of well-oxygenated tumor cells. Treatments with carbogen breathing alone, with Oxygent plus air-breathing, or with a vehicle emulsion containing all the components except the perfluorocarbon did not produce comparable improvements in tumor radiosensitivity. Concentrated perfluorooctylbromide emulsions appear to warrant further development and preclinical testing as adjuncts to cancer therapy.